IMRX Quote, Financials, Valuation and Earnings

Intensity Therapeutics has a net margin of -- compared to Immuneering's net margin of --. Immuneering's return on equity of -- beat Intensity Therapeutics's return on equity of --.

Immuneering has a consensus price target of $11.42, signalling upside risk potential of 188.3%. On the other hand Intensity Therapeutics has an analysts' consensus of $3.50 which suggests that it could grow by 975.93%. Given that Intensity Therapeutics has higher upside potential than Immuneering, analysts believe Intensity Therapeutics is more attractive than Immuneering.

Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intensity Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intensity Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. Intensity Therapeutics pays out -- of its earnings as a dividend.

Immuneering quarterly revenues are --, which are smaller than Intensity Therapeutics quarterly revenues of --. Immuneering's net income of -$15M is lower than Intensity Therapeutics's net income of -$3.3M. Notably, Immuneering's price-to-earnings ratio is -- while Intensity Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 393.82x versus -- for Intensity Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Immuneering's net margin of -49.65%. Immuneering's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Immuneering has a consensus price target of $11.42, signalling upside risk potential of 188.3%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Immuneering has higher upside potential than NovaBay Pharmaceuticals, analysts believe Immuneering is more attractive than NovaBay Pharmaceuticals.

Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Immuneering quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Immuneering's net income of -$15M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Immuneering's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 393.82x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Immuneering's net margin of --. Immuneering's return on equity of -- beat Oragenics's return on equity of --.

Immuneering has a consensus price target of $11.42, signalling upside risk potential of 188.3%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Immuneering, analysts believe Oragenics is more attractive than Immuneering.

Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Immuneering quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Immuneering's net income of -$15M is lower than Oragenics's net income of -$2.2M. Notably, Immuneering's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 393.82x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Immuneering's net margin of --. Immuneering's return on equity of -- beat Theriva Biologics's return on equity of --.

Immuneering has a consensus price target of $11.42, signalling upside risk potential of 188.3%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Immuneering, analysts believe Theriva Biologics is more attractive than Immuneering.

Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Immuneering quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Immuneering's net income of -$15M is lower than Theriva Biologics's net income of -$4.3M. Notably, Immuneering's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 393.82x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.